Ovarian cancer remains a major health problem in the United States and most Western European countries. Despite the availability of several effective chemotherapeutic agents for the treatment of ovarian cancer, survival is still poor. Major problems in ovarian cancer chemotherapies are a failure to consolidate response, acquired/intrinsic drug resistance, and dose-limiting toxicity. Thus new therapeutic treatment modalities have been developed, most of which are based on the targeting ability of monoclonal antibodies ( MAbs) that detect tumor-associated antigens. After early disappointments, some relevant clinical success has recently been achieved, and several alternative and/ or supplementary approaches are being explored. For detailed information on aspects such as mechanisms of action, preclinical screening, and clinical results, see specific references in Table 1 and an excellent recent review (1).